

ST.JUDE-**viva** Survivorship  
SERIES 2

Webinar #5:

# MONITORING SURVIVORS TREATED WITH NEW THERAPEUTIC MODALITIES:

## Estimating risks from early toxicity signals

3rd Feb 2023 | 8:30PM-10:00PM (UTC +8 | Singapore Time)

<b>Program Name:</b>	St. Jude-VIVA Survivorship Series 2 Webinar #5
<b>Event Date:</b>	Friday 3 <sup>rd</sup> February 2023
<b>Event Time:</b>	8:30pm – 10:00pm (Singapore Time)

## Programme Synopsis

### Lecture Title:

**Monitoring survivors treated with new therapeutic modalities: Estimating risks from early toxicity signals**

*Dr Stephanie Smith, Stanford University*

With increasing use of targeted biologic therapies and immunotherapies in pediatric oncology practice, many clinicians and patients find themselves wondering about potential long-term and late effects. These agents are more tailored to the cancer than traditional cytotoxic chemotherapy and radiation therapy, so the hope is that they will cause fewer long-term health risks. In this talk, we will review the challenges of evaluating long-term health risks of new therapies, principles for estimating early toxicity signals, and the process that we are using in the Children's Oncology Group Long-Term Follow-Up Guidelines New Agents Taskforce to estimate risks and develop recommendations for monitoring. We will use two classes of new agents as examples: BCR-ABL tyrosine kinase inhibitors and B-cell directed antibody-based therapies. Finally, we will close with some thoughts on strategies to accelerate data-sharing and move the field forward.